{"schema_version":"secwatch.filing_event.v1","accession":"0001539497-24-000590","form_type":"8-K","ticker":null,"cik":"0001358403","company_name":"BELLICUM PHARMACEUTICALS, INC","filed_at":"2024-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.945425+00:00","generated_at":"2026-06-05T16:51:03.840590+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bellicum advances dissolution: all directors resign, Dave Maggio named CEO","bullets":["All five directors resigned effective Feb 23, 2024; Richard Fair remains sole director.","CEO Richard Fair resigned; Dave Maggio appointed CEO effective same day.","Consulting agreement with Fair extended to June 30, 2024.","Stockholders approved dissolution plan on Feb 20, 2024; company winding down.","Resignations not related to any disagreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001539497-24-000590","json":"https://secwatch.observer/filing/0001539497-24-000590.json","markdown":"https://secwatch.observer/filing/0001539497-24-000590.md","text":"https://secwatch.observer/filing/0001539497-24-000590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/n3936_x24-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:51:03.840590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"151cbbdd56","claim":"Jon P. Stonehouse resigned as Director at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"· Jon P. Stonehouse ( Audit Committee and Compensation Committee )","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2ce74892f0","claim":"Charity D. Scripture resigned as Chief Development Officer at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"Charity D. Scripture resigned as Chief Development Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"3d7b4c7cca","claim":"James M. Daly resigned as Director at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"each of the Company’s directors listed below submitted their resignation from the Board and the committees thereof opposite their name below, effective as of February 23, 2024. · Mr. James M. Daly ( Compensation Committee, Nominating Committee and Finance Committee )","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"44ea8444e4","claim":"Richard A. Fair resigned as President and Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"Mr. Richard A. Fair resigned as President and Chief Executive Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"60f4bbb91e","claim":"Reid M. Huber resigned as Director at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"· Reid M. Huber, Ph.D. ( Audit Committee, Nominating Committee, Science Committee and Finance Committee )","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8edc259a8a","claim":"Dave Maggio was appointed as Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"the Board appointed Dave Maggio to the position of Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a131d8b899","claim":"Judith Klimovsky resigned as Director at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"· Judith Klimovsky M.D. ( Nominating Committee, Science Committee and Finance Committee )","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b36cbb135b","claim":"Stephen R. Davis resigned as Director at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"· Stephen R. Davis ( Audit Committee )","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b6ddbbdba1","claim":"Charles S. Grass resigned as Principal Accounting Officer at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"Charles S. Grass resigned as Principal Accounting Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000590/0001539497-24-000590-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}